Allogene Therapeutics has entered an exclusive collaboration with Antion Biosciences to use Antion's miCAR technology for developing next-generation allogeneic CAR T therapies, potentially accelerating advancements in cancer treatment.

Overview of Antion Biosciences

Antion Biosciences SA is an innovative Swiss company specializing in cell and gene engineering. The company is focused on developing advanced multiplexed allogeneic therapies that aim to address diseases with significant unmet medical needs. With proprietary technologies such as Tunable Expression Modulators (TEM) and miCAR™, Antion has positioned itself at the forefront of cell engineering, allowing for efficient multi-gene silencing and gene addition in a single step. This capability supports the creation of multimodal treatments designed to enhance clinical safety and efficacy.

Antion's miCAR technology has shown promise in preclinical studies, demonstrating the ability to silence multiple gene targets simultaneously in an allogeneic CAR T cell model, highlighting its potential applicability within the broader scope of cell and gene engineering.

Industry Overview in Switzerland

The biotechnology industry in Switzerland is recognized for its high level of innovation and research capabilities. With a robust ecosystem that includes leading academic institutions, research centers, and a concentration of established biot